Joseph Tuscano
Overview
Explore the profile of Joseph Tuscano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
361
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Othman T, Marquez-Arreguin G, Esteghamat N, Tuscano J
Leuk Lymphoma
. 2024 Dec;
:1-4.
PMID: 39731545
No abstract available.
2.
Esteghamat N, Tsumura A, Marquez-Arreguin G, Tuscano J
Front Oncol
. 2024 Nov;
14:1481950.
PMID: 39502312
Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL) is an aggressive disease with poor prognosis and limited therapeutic options. High-dose chemotherapy with autologous hematopoietic stem cell transplantation (autoHCT) was historically the...
3.
Othman T, Frankel P, Allen P, Popplewell L, Shouse G, Siddiqi T, et al.
Haematologica
. 2024 Jul;
110(1):142-152.
PMID: 39021209
Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) transformed from indolent B-cell lymphomas, including Richter transformation, have a poor prognosis. PD-1/PD-L1 antibodies produce modest objective and complete response rates in...
4.
Durando M, Gopal A, Tuscano J, Persky D
Oncologist
. 2024 Jan;
29(4):278-288.
PMID: 38207010
Purpose: The clinical efficacy of anti-CD20 radioimmunotherapy (RIT) is due to a combination of extracellular mechanisms involving immune-mediated cytotoxicity, and intracellular mechanisms related to inhibition of CD20 signaling and DNA...
5.
Zelenetz A, Gordon L, Abramson J, Advani R, Andreadis B, Bartlett N, et al.
J Natl Compr Canc Netw
. 2023 Nov;
21(11):1118-1131.
PMID: 37935098
Novel targeted therapies (small molecule inhibitors, antibody-drug conjugates, and CD19-directed therapies) have changed the treatment landscape of relapsed/refractory B-cell lymphomas. Bruton's tyrosine kinase (BTK) inhibitors continue to evolve in the...
6.
Othman T, Lowsky R, Richman C, Hoeg R, Abedi M, Tuscano J
Bone Marrow Transplant
. 2023 Jun;
58(10):1143-1145.
PMID: 37391654
No abstract available.
7.
Othman T, Quan M, Zhang S, Gaut D, Young P, Mahmood O, et al.
Clin Lymphoma Myeloma Leuk
. 2023 Jun;
23(10):749-756.
PMID: 37336714
Background: The choice between nonmyeloablative chemotherapy (NMA-C) or autologous hematopoietic cell transplantation (autoHCT) as consolidation in primary central nervous system lymphoma (PCNSL), and timing of autoHCT differs among centers. We...
8.
Othman T, Penaloza J, Zhang S, Daniel C, Gaut D, Oliai C, et al.
Clin Lymphoma Myeloma Leuk
. 2022 Jul;
22(10):e947-e957.
PMID: 35858904
Background: Managing double-expressor lymphomas (DEL) is controversial given the dearth of data and lack of standardized guidelines on this high-risk subset of lymphomas. No prospective and few retrospective studies limited...
9.
Virk H, Shahlaie K, Ramani B, Perry A, Fragoso R, Tuscano J, et al.
J Neuroophthalmol
. 2022 Apr;
42(1):e293-e296.
PMID: 35475853
No abstract available.
10.
Poh C, McPherson J, Tuscano J, Li Q, Parikh-Patel A, Vogel C, et al.
BMC Med
. 2022 Apr;
20(1):165.
PMID: 35468782
Background: There is evidence indicating that pesticide exposure is a risk factor for non-Hodgkin lymphoma (NHL) development. However, the association between pesticide exposure and NHL survival is not well-established. Methods:...